120 related articles for article (PubMed ID: 32088019)
21. Estimating seroprevalence of human papillomavirus type 16 using a mixture model with smoothed age-dependent mixing proportions.
Vink MA; van de Kassteele J; Wallinga J; Teunis PF; Bogaards JA
Epidemiology; 2015 Jan; 26(1):8-16. PubMed ID: 25380503
[TBL] [Abstract][Full Text] [Related]
22. Predictors of seropositivity to human papillomavirus type 53: one of the most prevalent high risk-related cervical human papillomaviruses.
Malik ZA; Hailpern SM; Burk RD
Viral Immunol; 2008 Sep; 21(3):371-7. PubMed ID: 18681800
[TBL] [Abstract][Full Text] [Related]
23. Seroprevalence and Associated Factors of 9-Valent Human Papillomavirus (HPV) Types among Men in the Multinational HIM Study.
Rahman S; Pierce Campbell CM; Rollison DE; Wang W; Waterboer T; Michel A; Pawlita M; Villa LL; Lazcano Ponce E; Borenstein AR; Giuliano AR
PLoS One; 2016; 11(11):e0167173. PubMed ID: 27902759
[TBL] [Abstract][Full Text] [Related]
24. [Distribution of serum antibodies against human papillomavirus 16 and 18 among high-risk women to cervical cancer].
Fei M; Li J; Du J; You J; Zhang S; He W; Kang L; Zhao F; Qiao Y; Si Y; Fan X; Chen W
Zhonghua Liu Xing Bing Xue Za Zhi; 2014 May; 35(5):514-8. PubMed ID: 25059358
[TBL] [Abstract][Full Text] [Related]
25. Seroprevalence of human papillomavirus types 6, 11, 16 and 18 in Chinese women.
Ji J; Sun HK; Smith JS; Wang H; Esser MT; Hu S; Pretorius RG; Chen W; Belinson JL; Qiao YL
BMC Infect Dis; 2012 Jun; 12():137. PubMed ID: 22715915
[TBL] [Abstract][Full Text] [Related]
26. Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up.
Huang T; Liu Y; Li Y; Liao Y; Shou Q; Zheng M; Liao X; Li R
Vaccine; 2018 Mar; 36(11):1368-1374. PubMed ID: 29428178
[TBL] [Abstract][Full Text] [Related]
27. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004.
Markowitz LE; Sternberg M; Dunne EF; McQuillan G; Unger ER
J Infect Dis; 2009 Oct; 200(7):1059-67. PubMed ID: 19719390
[TBL] [Abstract][Full Text] [Related]
28. Age-specific seroprevalence of human papillomavirus 16, 18, 31, and 58 in women of a rural town of Colombia.
Bedoya AM; Gaviria AM; Baena A; Borrero M; Duarte DF; Combita AL; Castaño J; Grisales H; Sánchez GI
Int J Gynecol Cancer; 2012 Feb; 22(2):303-10. PubMed ID: 22228426
[TBL] [Abstract][Full Text] [Related]
29. Gender and age-specific seroprevalence of human papillomavirus 16 and 18 in general population in Tehran, Iran.
Aghakhani A; Mamishi S; Sabeti S; Bidari-Zerehpoosh F; Banifazl M; Bavand A; Ramezani A
Med Microbiol Immunol; 2017 Apr; 206(2):105-110. PubMed ID: 27858157
[TBL] [Abstract][Full Text] [Related]
30. A Bivariate Mixture Model for Natural Antibody Levels to Human Papillomavirus Types 16 and 18: Baseline Estimates for Monitoring the Herd Effects of Immunization.
Vink MA; Berkhof J; van de Kassteele J; van Boven M; Bogaards JA
PLoS One; 2016; 11(8):e0161109. PubMed ID: 27537200
[TBL] [Abstract][Full Text] [Related]
31. Seroprevalence of Human Papillomavirus (HPV) Type 6, 11, 16, 18, by Anatomic Site of HPV Infection, in Women Aged 16-64 Years living in the Metropolitan Area of San Juan, Puerto Rico.
Pérez-Caraballo AM; Suarez E; Unger ER; Palefsky JM; Panicker G; Ortiz AP
P R Health Sci J; 2018 Mar; 37(1):26-31. PubMed ID: 29547681
[TBL] [Abstract][Full Text] [Related]
32. Predictors of Human Papillomavirus Seropositivity in Appalachian Women Aged 18 to 26 Years.
Ruffin MT; Hade EM; Fahey P; Christian LM; Paskett ED; Harper DM
Sex Transm Dis; 2021 Sep; 48(9):693-699. PubMed ID: 34106566
[TBL] [Abstract][Full Text] [Related]
33. Human papillomavirus-specific antibody status among unvaccinated subjects in the region of Vojvodina, Serbia.
Kovačević G; Božić Nedeljković B; Patić A; Radovanov J; Hrnjaković-Cvjetković I
Cent Eur J Public Health; 2023 Mar; 31(1):57-62. PubMed ID: 37086422
[TBL] [Abstract][Full Text] [Related]
34. Seroepidemiology of infection with human papillomavirus 16, in men and women attending sexually transmitted disease clinics in the United States.
Thompson DL; Douglas JM; Foster M; Hagensee ME; Diguiseppi C; Barón AE; Cameron JE; Spencer TC; Zenilman J; Malotte CK; Bolan G; Kamb ML; Peterman TA;
J Infect Dis; 2004 Nov; 190(9):1563-74. PubMed ID: 15478060
[TBL] [Abstract][Full Text] [Related]
35. Population-Level Herd Protection of Males From a Female Human Papillomavirus Vaccination Program: Evidence from Australian Serosurveillance.
Pillsbury AJ; Quinn HE; Evans TD; McIntyre PB; Brotherton JML
Clin Infect Dis; 2017 Sep; 65(5):827-832. PubMed ID: 29017279
[TBL] [Abstract][Full Text] [Related]
36. Risk factors for cutaneous human papillomavirus seroreactivity among patients undergoing skin cancer screening in Florida.
Iannacone MR; Michael KM; Giuliano AR; Waterboer T; Pawlita M; Rollison DE
J Infect Dis; 2010 Mar; 201(5):760-9. PubMed ID: 20105078
[TBL] [Abstract][Full Text] [Related]
37. Gender differences in sexual biomarkers and behaviors associated with human papillomavirus-16, -18, and -33 seroprevalence.
Kreimer AR; Alberg AJ; Viscidi R; Gillison ML
Sex Transm Dis; 2004 Apr; 31(4):247-56. PubMed ID: 15028941
[TBL] [Abstract][Full Text] [Related]
38. Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV).
Gray P; Luostarinen T; Vänskä S; Eriksson T; Lagheden C; Man I; Palmroth J; Pimenoff VN; Söderlund-Strand A; Dillner J; Lehtinen M
Int J Cancer; 2019 Aug; 145(3):785-796. PubMed ID: 30719706
[TBL] [Abstract][Full Text] [Related]
39. Seroprevalence of human papillomavirus 6, 11, 16, and 18 in young primiparous women in Sao Paulo, Brazil.
Rama CH; Villa LL; Pagliusi S; Andreoli MA; Costa MC; Thomann P; Longatto-Filho A; Eluf-Neto J
Int J Gynecol Cancer; 2010 Nov; 20(8):1405-10. PubMed ID: 21051985
[TBL] [Abstract][Full Text] [Related]
40. Mucosal and cutaneous Human Papillomavirus seroprevalence among adults in the prevaccine era in Germany - Results from a nationwide population-based survey.
Loenenbach AD; Poethko-Müller C; Pawlita M; Thamm M; Harder T; Waterboer T; Schröter J; Deleré Y; Wichmann O; Wiese-Posselt M
Int J Infect Dis; 2019 Jun; 83():3-11. PubMed ID: 30904676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
